We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT. The median age was 39 years (range, 3-69), and stem cell source was bone marrow (n ¼ 31), or peripheral blood progenitor cells (n ¼ 30), or the combination of both (n ¼ 4). The primary disease was solid tumors (n ¼ 37), Hodgkin's disease (n ¼ 13), non-Hodgkin's lymphoma (n ¼ 10), acute lymphoblastic leukemia (n ¼ 2) or myeloproliferative syndromes (n ¼ 3). The types of MDS were as follows: RAEB (n ¼ 1; 2%), RAEB-t (n ¼ 3; 5%), or AML (n ¼ 56; 87%). The median time between diagnosis and transplantation was 5 months (range, 3-86). The Kaplan-Meier estimates of the probability of 3-year overall and diseasefree survival were 35% (95% CI: 21-49%) and 32% (95% CI: 18-45%), respectively. The median leukocyte engraftment was faster after transplantation with peripheral blood stem cells than with bone marrow: 12 (range, 9-26) vs 29 (range, 11-67) days (Po0.001). The cumulative incidence of relapse was 58% (95% CI: 44-72%) and of treatment-related mortality 12% (95% CI: 6-38%). Lower relapse rate was seen in patients transplanted in first complete remission (CR 1 vs non-CR 1 : 3 years: 48 vs 89%; P ¼ 0.05). Furthermore, age beyond 40 years resulted in a higher treatment-related mortality (47 vs 7%; P ¼ 0.01). In a multivariate analysis, transplantation in CR 1 age as well as their interaction influenced overall survival significantly. Autologous transplantation may cure a substantial number of patients with treatmentrelated MDS/AML, especially if they are in CR 1 and of younger age.
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Introduction
Chemotherapy and/or radiotherapy as part of a multimodal therapy as treatment approach in cancer patients has led to an increase in the curing rate. However, after successful treatment of cancer, late effects such as therapyrelated myelodysplastic syndrome (t-MDS) or acute myeloid leukemia (t-AML) have emerged as a significant problem. 1 Along with the increasing cure rate for some malignancies due to intensified chemotherapies, including total body irradiation and autologous stem cell support, there appears to be an increasing incidence of t-MDS or t-AML. 2 Two different types of treatment-related leukemia could be distinguished. The first type resulted from prior therapy with alkylating agents or radiation therapy and occurred after a latency period of 5-7 years. This type of AML is often preceded by a preleukemic period of myelodysplasia (MDS). Up to 90% of the patients with alkylating-agent-related MDS or AML show clonal chromosome aberrations including monosomy or deletions on chromosomes 5 and/or 7 or complex aberrations involving chromosome 3, 12, 17, and 21. 3 The second type of therapyrelated leukemia is induced by topoisomerase II-targeted drugs like etoposide, anthracyclines, or recently anthracenedione. [4] [5] [6] This type of AML usually occurred after a median of 2 years and is not preceded by a MDS. According to the French-American-British (FAB) classification, M4 or M5 is observed more frequently, and cytogenetic analysis showed a high frequency of rearrangements of chromosome band 11q23, t(8;21), t(15;17), inv (16) , or t (8;16) as in de novo AML. 6, 7 Primary MDS, AML after MDS, and t-MDS/-AML share biologic and clinical features, but t-MDS/AML has a more rapidly progressive disease and a worse response to chemotherapy. 8 Treatment with growth factors, retinoids or interferons, did not result in an improved overall survival (OS). 9 Intensive chemotherapy in t-MDS/AML resulted in a lower rate of complete remission (CR) and a shorter duration of remission in comparison to de novo MDS/AML. 10 In a review of 644 patients with t-AML treated with standard-AML-induction protocols, only 28% achieved a CR. 11 Importantly, a small number of patients with t-AML who have favorable cytogenetic abnormalities, such as t(8;21), t(15;17), or inv (16) , have a considerably better outcome, not markedly different from the high response rate observed with the same abnormalities in de novo AML. 12 Allogeneic stem cell transplantation is proposed to be the only curative treatment approach in t-MDS/AML. In the largest series of allogeneic stem cell transplantation in sMDS/AML, 2-year event-free and OS of 28 and 30% have been reported. 13 In the present retrospective analysis, we report about the results and risk factors of autologous stem cell transplantation in t-MDS/-AML who were reported to the European Blood and Marrow Transplantation Group.
Patients and methods
Between November 1991 and November 2000, 65 patients (23 male and 42 female) with treatment-related myelodysplastic syndromes (t-MDS) or treatment-related AML (t-AML) underwent autologous stem cell transplantation and were reported to the EBMT registry. Twenty-one patients had been included in a previous EBMT analysis of 79 patients who received autolgous stem cell transplantation for MDS and are now included with a longer followup.
14 The median age of the patients was 39 years (range, 3-69), and primary disease were solid tumors (n ¼ 37), Hodgkin's disease (n ¼ 13), non-Hodgkin's disease (n ¼ 10), myeloproliferative syndrome (n ¼ 3), and acute lymphoblastic leukemia (n ¼ 29). For primary diagnosis, the treatment consisted of chemotherapy (n ¼ 38), chemotherapy plus radiotherapy (n ¼ 18), only radiotherapy (n ¼ 2), or high-dose chemotherapy followed by autologous stem cell support (n ¼ 1). The time from primary diagnosis to t-MDS/t-AML was 43 months (range, 0-284 months) and from t-MDS/t-AML to autologous stem cell transplantation 5 months (range, 3-86). Most of the patients (n ¼ 56) had acute myeloid leukemia without preceding MDS, and only four patients had RAEB (n ¼ 1) or RAEB-t (n ¼ 3) at diagnosis. All patients received anthracycline-/ anthracenedione-and cytarabine-based induction chemotherapy prior to autologous stem cell transplantation. At the time of transplantation, 46 of the patients were in CR 1 , eight in CR 2 , while six patients had refractory or relapsed disease. Peripheral blood stem cells served as graft source in 30 patients, and bone marrow was used in 31 of the patients. Four patients received bone marrow and peripheral blood stem cells. Cytogenetic analysis was available in 34 patients and is shown in Table 1 . Normal karyotype, inversion 16, and t(8;21) were classified as low risk, all others as intermediate/high risk.
Study end points
Primary end points of this retrospective study were diseasefree survival and OS after autologous stem cell transplantation in t-MDS/t-AML patients. Hematopoietic recovery of lekcocytes and platelets were also described. The secondary aim was to analyze prognostic factor within a univariate and multivariate analysis with respect to treatment-related mortality, relapse rate, overall and disease-free survival. Hematopoietic recovery was defined as the first of three consecutive days with an absolute neutrophils count of Table 1 Patients' characteristics Number of patients 65
Median interval from diagnosis of t-MDS/t-AML to autologous stem cell transplantation 5 months (range, 3-86)
Interval from primary diagnosis to autologous stem cell transplantation
0.5 Â 10 9 /l, the date of platelet recovery was defined as the first of seven consecutive days with a platelet count 420 Â 10 9 /l without transfusion. Criteria for relapse were hematological relapses.
Statistical analyses
The time intervals for survival, relapse-free survival (RFS), relapse rate, and transplant-related mortality (TRM) were calculated and expressed as the number of months between stem cell transplantation and the event of interest. For the Kaplan-Meier curves (used in univariate descriptions) and COX models (used to estimate Hazard ratios), the relapsed patients were censored for TRM at the time of relapse and vice versa. Univariate comparison of Kaplan-Meier curves was performed using the two-tailed log-rank test. For ordered categorical variables, the trend version of the logrank test was used. The association of various risk factors such as age, remission status at transplantation, stem cell source, time from diagnosis to transplantation, stage of the disease, and TBI-containing conditioning with the outcomes OS, RFS, relapse incidence (RI), and TRM was quantified using the Hazard ratios estimated in COX models.
For the purpose of comparison with other publications and in order to obtain valid (nonbiased) estimates for the actual probability of the competing risks of relapse and death in remission, estimates for RI and TRM were made using cumulative incidence estimates. The sum of the RI and TRM cumulative incidences equals the (complement of the) RFS. Calculations were performed in SPSS version 11. The cumulative incidences were calculated in NCSS version 2001.
Results

Engraftment
Engraftment data were available for 52 patients. The median time to neutrophil recovery (40.5 Â 10 9 /l) was 15 days (range, 9-67 days) and for platelets (450 Â 10 9 /l) was 40 days (range, 9-301 days). The median leukocyte engraftment was faster after transplantation with peripheral blood stem cells than with bone marrow: 12 (range, 9-26) vs 29 (range, 11-67) days (Po0.001).
TRM
Based on a cumulative incidence calculation, the treatmentrelated mortality at 2 years was 12% (95% CI: 6-38%) (Figures 1 and 2) . In a univariate analysis, younger age (o40 years) was associated with a lower TRM (7 vs 47%; P ¼ 0.007), while peripheral blood stem cells as graft source resulted in a lower TRM with borderline significance in comparison to bone marrow (5 vs 32%; P ¼ 0.07) ( Table 2) . In a multivariate analysis, however, peripheral blood stem cells as graft source was a significant factor for lower TRM (HR: 0.10; 95% CI: 0.01-0.9; P ¼ 0.05) ( Table 3) .
Relapse
Based on a cumulative incidence calculation in a competing risk setting (between relapse and death-in-remission), the 5-year cumulative incidence for relapse ( ¼ RI) is 58% (95% CI: 44-72%) (Figures 1 and 3) . In a univariate analysis, only remission status prior to transplantation (CR 1 vs non-CR 1 ) had a lower relapse risk (48 vs 83%; P ¼ 0.05) ( Table 2 ). In a multivariate analysis, the relapse rate was significantly lower for patients transplanted in CR 1 (HR 0.4; 95% CI: 0.14-0.88; P ¼ 0.03) ( Table 3) .
Disease-free survival
The 3-year disease-free survival for the entire group was 32% (95% CI: 18-45%) (Figure 4) . Within the univariate analysis, transplantation in CR 1 vs non-CR 1 resulted in a better disease-free survival (41 vs 9%, P ¼ 0.04) ( Table 2) . In a multivariate analysis, transplantation in CR 1 (HR: 0.3; 95% CI: 0.13-0.71; P ¼ 0.006) and increasing age (HR 1.028; 95% CI: 1.004-1.053; P ¼ 0.02) did significantly influence the disease-free survival (Table 3) . Relapse TRM Figure 1 Cumulative incidence of relapse and treatment-related mortality for the whole study population (in a competing risk model).
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OS
The estimated 3-year OS was 35% (95% CI: 21-49%) ( Figure 5 ). In a univariate analysis, age 440 years (19 vs 47%; P ¼ 0.01) and receiving a non-TBI-containing regimen (33 vs 53%; P ¼ 0.04) resulted in a significant lower probability of OS (Table 2) . In a multivariate analysis, an OS was significantly influenced by CR 1 at transplantation (HR 0.4; 95% CI: 0.16-0.9; P ¼ 0.04) and by age (HR 1.03; 95% CI: 1.01-1.06; P ¼ 0.008) ( Table 3) . There was also an interaction between age and transplantation in CR 1 . The net result is that CR 1 has no effect among patients of 20 years of age (HR 0.9) and increases its effect with increasing age until it reaches an estimated HR of 0.1 around 60 years of age. Therefore, the estimated 3-year survival for patients of 20 years of age is about 50% for CR 1 vs 50% in non-CR 1 , but for a patient of 50 years of age, the estimated 3-year survival amounts to approximately 30% in CR 1 vs 0% for non-CR 1 .
Discussion
This retrospective study shows that autologous stem cell transplantation is a curative therapy option for some Table 3 Multivariate analysis OS % (95% CI) P-value DFS % (95% CI) P-value Relapse % (95% CI) P-value TRM % (95% CI patients with t-AML resulting in a 3-year event-free and OS of 29 and 35%, respectively. The probability for event-free and OS exceeds about 40% in those patients who were younger than 40 years and in CR 1 . These results are comparable with the results obtained after allogeneic stem cell transplantation for t-MDS/AML reported by the EBMT and the French Society of Bone Marrow Transplantation; in the study of the EBMT, a 3-year probability of disease-free survival of 35% was reported for patients transplanted for t-MDS/AML (n ¼ 67) for HLA-identical siblings, which did not differ significantly from the patients transplanted for primary MDS (37%, n ¼ 712) or secondary AML (32%, n ¼ 106). 15 The French Society of Bone Marrow Transplantation reported for 70 patients with t-MDS/-AML a 28% event-free survival at 2 years after allogeneic stem cell transplantation from related and unrelated donors. 13 In a small single-center study including 18 patients with MDS, the disease-free survival after allogeneic stem cell transplantation was only 24% for t-MDS in comparison to 43% for primary MDS. 16 However, one might keep in mind that the patient population in our study is highly selected including mostly patients with AML at diagnosis, who were chemosensitive and in CR at the time of transplantation. Similar to the reported risk factor for allogeneic stem cell transplantation in t-MDS/t-AML, 13 lower age and CR are most important risk factors for OS after autologous stem cell transplantation. Intensive chemotherapy for t-MDS/t-AML resulted in a lower rate of CR in comparison to de novo AML; therefore, most of the treated patients probably did not reach CR and no stem cell transplantation was performed. However, there was also an interaction between age and transplantation in CR 1 : The net result is that CR 1 has no effect among patients who are 20 years of age (HR 0.9) and increases its effect with increasing age until it reaches an estimated HR of 0.1 around 60 years of age. Therefore, the estimated 3-year survival for patients of 20 years of age is about 50 vs 50% for CR 1 and non-CR 1 , but for a patient of 50 years of age, the estimated 3-year survival amounts to approximately 30% in CR 1 vs 0% for non-CR 1 . However, in view of the limited size of our population and the missing data about further treatment, such as allogeneic stem cell transplantation, we did not include the interaction in the final models. Several cooperative AML study groups reported a worse OS for t-AML in comparison to de novo AML. An analysis by the Medical Research Council 17 (MRC) found a significantly shorter OS for patients with t-AML (30 vs 44%) which was in line with the results of the German AML Cooperative group reporting a median survival of 10 months for t-AML in comparison to 15 months for de novo AML (P ¼ 0.001). 18 This study highlighted the impact of karyotype aberrations in patients with t-AML. In a recent update, t-AML with favorable karyotype had a significantly better median survival than those patients with an unfavorable karyotype (26.7 vs 5.6 months; P ¼ 0.02). 19 Owing to the limited number of patients with available cytogenetics, this factor has not reached statistical significance in our analysis. However, the estimated OS for those eight patients with favorable karyotype (inv 16 or t(8;21)) was 57% (95% CI: 29-97%), supporting the prognostic impact of cytogenetics in treatment-induced MDS or AML.
The value of autologous stem cell transplantation in MDS/sAML as treatment option remains still unclear and Autologous stem cell transplantation for t-MDS/AML N Kröger et al only few patients with primary MDS/sAML who underwent autologous transplantation were reported so far. The EBMT reported a 34% disease-free survival in 79 patients after autologous stem cell transplantation. 14 In this group of patients, the incidence of relapse was 55%. Patients with an age younger than 40 years had a significantly better disease-free survival than patients older than 40 years (39 vs 25%, P ¼ 0.04). A prospective French study investigated the feasibility of autologous stem cell transplantation after conditioning with busulfan and cyclophosphamide in those patients who achieved a CR after induction chemotherapy, and the study reported about 50% of the patients who were alive 8-55 months after transplantation. 20 More recently, the EORTC presented results from 159 patients with MDS who received a transplant from a HLA-identical sibling or (if not available) an autologous transplantation after induction chemotherapy. The 4-year RFS was 23% for patients with a donor and 22% for patients without a donor (P ¼ 0.7), and the authors concluded that allogeneic and autologous stem cell transplantation result in similar survival rates.
In conclusion, these data from the retrospective study suggest that autologous stem cell transplantation for t-MDS/-AML can result in the long-term freedom from disease, especially in younger patients with CR after induction chemotherapy and should be considered as treatment option if no HLA donor is available. However, from this registry data, no information about patient selection is available and therefore no definite conclusion as to which treatment should be offered to those patients can be drawn.
